TMDX - TransMedics Group Inc logo

TMDX

TransMedics Group Inc

Revenue grew 100% of years5Y
Hold

TransMedics Group develops and commercializes the Organ Care System (OCS), a portable technology for organ preservation and monitoring, enabling improved transplantation of hearts, lungs, and livers for patients with end-stage organ failure.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$2,878today

Score Overview

1 Year
Score
Net Growth-20.28%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth10.40%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.5
Net Growth443.09%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth22x
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Score
Net Growth6x
Net Trend71%
Net Income Consistency
Rev Growth28x
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

TransMedics Group Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 25M to $ 605M and net income went from -$ 28M to $ 190M. Revenue increased in every one of those 5 years; net income in 4.

TransMedics Group Inc currently holds a 5-year HDB Score of 8.5 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 87.02โ€”
1 Year2025-08-12
$ 131.13-33.64%
5 Years2021-08-12
$ 30.24187.76%
All Time2019-05-02
$ 22.36289.18%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 668M$ 151M$ 472M
2025$ 605M$ 190M$ 488M
2024$ 441M$ 35M$ 336M
2023$ 241M-$ 25M$ 394M
2022$ 93M-$ 36M$ 201M
2021$ 30M-$ 44M$ 92M
2020$ 25M-$ 28M$ 125M
IPO2019$ 23M-$ 33M$ 80M

Explore beyond TMDX

You're looking at TransMedics Group Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies